Horizon Therapeutics Publ... (HZNP)
NASDAQ: HZNP
· Real-Time Price · USD
116.30
0.00 (0.00%)
At close: Jan 16, 2025, 10:00 PM
Horizon Therapeutics Public Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | 3.64B | 3.58B | 3.63B | 3.7B | 3.81B | 3.77B | 3.23B | 2.96B | 2.56B | 2.19B |
Cost of Revenue | 903.44M | 913.7M | 920.2M | 920.92M | 938.43M | 909.21M | 794.51M | 715.29M | 615.13M | 535.65M |
Gross Profit | 2.74B | 2.66B | 2.71B | 2.78B | 2.87B | 2.86B | 2.43B | 2.24B | 1.94B | 1.65B |
Operating Income | 513.37M | 512.87M | 671.19M | 730.35M | 901.29M | 897.46M | 543.13M | 550.11M | 447.15M | 346.5M |
Interest Income | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Income | 443.86M | 373.4M | 526.94M | 583.66M | 755.82M | 806.67M | 462.83M | 481.32M | 375.84M | 263.16M |
Net Income | 438M | 371.9M | 521.48M | 574.26M | 764.96M | 862.1M | 534.49M | 551.87M | 518.16M | 280.04M |
Selling & General & Admin | 1.66B | 1.62B | 1.54B | 1.57B | 1.53B | 1.49B | 1.45B | 1.32B | 1.19B | 1.06B |
Research & Development | 515.77M | 468.98M | 437.96M | 461.35M | 440.84M | 477.43M | 431.99M | 361.96M | 298.61M | 239.85M |
Other Expenses | 404K | -6.17M | -5.57M | -5.73M | -4.3M | -2.17M | 1.79M | 3.71M | 5.28M | 6.17M |
Operating Expenses | 2.17B | 2.09B | 1.98B | 2.03B | 1.97B | 1.96B | 1.88B | 1.69B | 1.49B | 1.3B |
Interest Expense | 68.68M | 77.99M | 83.71M | 87.19M | 87.69M | 88.86M | 81.06M | 70.53M | 59.74M | 55.73M |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 3.08B | 3B | 2.9B | 2.95B | 2.91B | 2.87B | 2.67B | 2.4B | 2.1B | 1.83B |
Income Tax Expense | 5.86M | 1.49M | 5.45M | 9.41M | -9.14M | -55.44M | -71.66M | -70.55M | -142.32M | -16.88M |
Shares Outstanding (Basic) | 228.74M | 228.4M | 226.97M | 230.33M | 230.02M | 229.09M | 227.04M | 226.1M | 225.12M | 223.92M |
Shares Outstanding (Diluted) | 233.94M | 233.79M | 233.01M | 235.39M | 236.17M | 235.95M | 236.95M | 236.2M | 235.19M | 223.92M |
EPS (Basic) | 1.92 | 1.62 | 2.25 | 2.48 | 3.33 | 3.77 | 2.35 | 2.45 | 2.39 | 1.27 |
EPS (Diluted) | 1.87 | 1.59 | 2.23 | 2.44 | 3.24 | 3.65 | 2.23 | 2.32 | 2.25 | 1.16 |
EBITDA | 957.03M | 955.48M | 1.11B | 1.13B | 1.28B | 1.27B | 909.04M | 886.07M | 760.71M | 644.69M |
EBIT | 512.54M | 505.17M | 664.42M | 724.63M | 897.29M | 895.53M | 557.35M | 565.32M | 449.04M | 332.35M |
Depreciation & Amortization | 441.47M | 442.61M | 444.21M | 404.88M | 383.55M | 378.04M | 353.75M | 326.76M | 302.79M | 284.53M |